9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM

Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM

Estimated reading time: < 1 min

Condition: Advanced Malignant Pleural Mesothelioma

Estimated Enrollment: 137

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Progression-Free Survival (PFS),  Overall survival (OS),  Tumor response, Safety and Toxicity according to NCI-CTCAE criteria(version 4.03)

Interventions: NGR-hTNF, Placebo

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor),Primary Purpose: Treatment

Primary Completion Date: December 5, 2018

Completion Date: December 5, 2018

Last  Posted Date: January 15, 2019

Location: Zentralklinik Bad Berka GmbH, Bad Berka, Thuringia, Germany

Website Link: https://ClinicalTrials.gov/show/NCT01358084

Was this article helpful?
Dislike 0